BioAge Labs, Inc. (BIOA) stock
BIOANasdaqPharmaceutical PreparationsFiscal year ends December 31
$5.10−0.12 (-2.30%)
Close on Nov 17, 2026Market cap $234.07MP/E –Yield –
BioAge Labs operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
BioAge Labs's operating cash flow for the twelve months ending Jun 30, 2026 was -$87.60M. For fiscal 2025 it was -$81.63M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$81.63M | – |
| FY2024 | Dec 31, 2024 | -$51.52M | – |
| FY2023 | Dec 31, 2023 | -$37.36M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$19.26M | – |
| Q1 FY2026 | Mar 31, 2026 | -$24.05M | – |
| Q4 FY2025 | Dec 31, 2025 | -$28.25M | – |
| Q3 FY2025 | Sep 30, 2025 | -$16.04M | – |
| Q2 FY2025 | Jun 30, 2025 | -$19.97M | – |
| Q1 FY2025 | Mar 31, 2025 | -$17.36M | – |
| Q4 FY2024 | Dec 31, 2024 | -$5.14M | – |
| Q3 FY2024 | Sep 30, 2024 | -$14.93M | – |
| Q2 FY2024 | Jun 30, 2024 | -$15.78M | – |
| Q1 FY2024 | Mar 31, 2024 | -$15.67M | – |
| Q4 FY2023 | Dec 31, 2023 | -$8.50M | – |
See a number that looks wrong?